Thomson Reuters/Uni...
Health Care: Drugs
Zalicus Inc. (ZLCS: NASDAQ)
$0.60 -0.02 | -3.23%
05/17/13 - 03:58 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -44.33M | -42.04M | -35.04M | 15.39M |
| Operating Gains/Losses | -8.00K | 42.00K | 29.51M | 389.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.16M | -281.00K | 1.32M | 1.31M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 312.00K | 620.00K | 0.00 |
| (Decrease) Increase In Payables | 1.52M | -97.00K | -2.43M | -1.31M |
| (Decrease) Increase In Other Current Liabilities | -1.48M | 0.00 | -3.64M | -2.44M |
| (Increase) Decrease In Other Working Capital | -831.00K | 72.00K | 0.00 | -6.29M |
| Other Non-Cash Items | 1.67M | 1.72M | 2.62M | -33.59M |
| Net Cash From Continuing Operations | -38.49M | -33.38M | 18.68M | -23.91M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | -1.09M |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -38.49M | -33.38M | 18.68M | -24.99M |
| Sale of Property, Plant & Equipment | 308.00K | 43.00K | 97.00K | 588.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 125.55M | 156.88M | 342.58M | 111.29M |
| Purchases of Property, Plant & Equipment | -48.00K | -350.00K | -1.09M | -613.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 6.16M |
| Purchases of Short-Term Investments | -110.48M | -160.20M | -369.85M | -89.29M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 700.00K | -4.74M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 15.32M | -3.62M | -27.56M | 23.37M |
| Issuance of Debt | 0.00 | 16.98M | 2.87M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 29.24M | 20.32M | 484.00K | 2.00K |
| Repayment of Long-Term Debt | -4.29M | -364.00K | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | -391.00K | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | -26.00K | 0.00 |
| Net Cash From Financing Activities | 24.94M | 36.94M | 2.94M | 2.00K |
| Effect of Exchange Rate Changes | 2.00K | -12.00K | -9.00K | 18.00K |
| Net Change in Cash & Cash Equivalents | 1.78M | -70.00K | -5.96M | -1.60M |
Portfolios with ZLCS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserTrack1
- ContributorStocks Under-$10 Setting Up...
- User0730
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
Latest ZLCS Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar Higher 01.31.13 | 01:01 pm
- Acadia Pharma Selling Stock Ahead of Key Study Results 11.06.12 | 12:11 pm
- 8 Stocks Under $10 Making Big Moves 08.30.12 | 02:08 pm
- 5 Stocks Poised for Breakouts 08.10.12 | 01:08 pm
- 5 Stocks Under $10 Set to Soar 07.26.12 | 12:07 pm
- Horizon Pharma: Rayos FDA Approval Thursday Seems Likely 07.25.12 | 10:07 am
- Biotech Stock Mailbag: Zalicus, Amarin 07.13.12 | 06:07 am
- 7 Stocks Under $10 Streaking Higher 06.07.12 | 04:06 pm
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- 8 Stocks Under $10 Moving Higher 03.20.12 | 12:03 pm
Press Releases for ZLCS
- Zalicus Presents Data Demonstrating Advantages Of State-Dependent Ion Channel Screening - Business Wire 03.19.13 | 08:03 am
- Zalicus Reports Financial Results For The Fourth Quarter And Year End 2012 - Business Wire 03.06.13 | 07:03 am
- Zalicus Granted Composition-of-Matter Patent For Z944 - Business Wire 02.20.13 | 08:02 am
- Zalicus To Present At The 2013 BIO CEO & Investor Conference - Business Wire 02.05.13 | 08:02 am
- Zalicus Initiates The Second Of Two Phase 2a Studies With Z160 - Business Wire 01.03.13 | 07:01 am
- Zalicus To Present At The Oppenheimer 23rd Annual Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- Zalicus’ Z160 For Chronic Neuropathic Pain Selected As A Top 10 Project To Watch - Business Wire 11.27.12 | 08:11 am
- Zalicus Reports Financial Results For The Third Quarter 2012 - Business Wire 11.08.12 | 07:11 am
- Zalicus Licensee, Sanofi, Provides Status Update On Prednisporin (FOV1101) - Business Wire 10.25.12 | 07:10 am
- Zalicus Reports Top Line Phase 2b Trial Results With Synavive In Rheumatoid Arthritis - Business Wire 09.10.12 | 08:09 am
Partner Headlines for ZLCS
- A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships - Seeking Alpha 03.18.13 | 09:03 am
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- UPDATE: Rodman & Renshaw Downgrades Zalicus to Market Perform on Synavive Failure - Benzinga 09.11.12 | 01:09 pm
- Morning Market Losers - Benzinga 09.10.12 | 09:09 am
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS - NASDAQ 08.31.12 | 04:08 pm
- Zalicus: When Push Comes To Shove - Seeking Alpha 08.31.12 | 09:08 am
- Why Zalicus Buyers See $3 Again - Seeking Alpha 08.08.12 | 09:08 am
- 3 Rising Biotech Stars All Under $2/Share - Seeking Alpha 06.18.12 | 09:06 am
- Look For These 5 Biotech Stocks Heading North - Seeking Alpha 06.07.12 | 09:06 am
